Latest developments in coronary interventions

Czech version

Authors: O. Aschermann; M. Mates; K. Kopřiva
Authors‘ workplace: Kardiocentrum, Nemocnice Na Homolce, Praha
Published in: Kardiol Rev Int Med 2015, 17(3): 207-213
Category: Cardiology Review

Overview

Due to progress made in coronary interventions, we have seen over the last 20 years a dramatic improvement in early results and subsequent long‑term prognosis of patients treated with percutaneous coronary interventions. New generations of drug‑eluting stents (DES) and a wider use of new modalities for a more detailed imaging of the character of lesions in coronary arteries, as well as the concept of functional revascularization, have all brought about significant benefits. These new methods are used mainly in situations where angiography and stress tests cannot provide adequate information on actual haemodynamic significance of a coronary artery stenosis. This paper summarises the current state of knowledge about DES. We present key modalities to optimise PCI performance and provide a brief summary of recommendations for antithrombotic therapy after stent implantation in selected clinical settings.

Keywords:
coronary artery disease – intravascular ultrasound – fractional flow reserve – optical coherence tomography – drug‑eluting stents – polymer – antiaggregation

Sources

1. Moses JW, Leon MB, Pompa JJ et al. SIRIUS Investigators. Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315– 1323.

2. Mintz GS, Nissen SE, Anderson WD et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement, Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478– 1492.

3. Mates M, Hrabos V, Hajek P et al. Long‑term follow‑up after deferral of coronary intervention based on myocardial fractional flow reserve measurement. Coron Artery Dis 2005; 16: 169– 174.

4. White CW, Wright CB, Doty DB et al. Does visual interpretation of the coronary arteriogram predict thephysiological importance of a coronary stenosis. N Engl J Med 1984; 310: 819– 824.

5. Uren NG, Melin JA, De Bruyne B et al. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med 1994; 330: 1782– 1788.

6. Tonino PA, Fearon WF, De Bruyne B et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010; 55: 2816– 2821. doi: 10.1016/ j.jacc.2009.11.096.

7. Bech GJ, De Bruyne B, Pijls NH et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation 2001; 103: 2928– 2934.

8. Pijls NH, De Bruyne B, Peels K et al. Measurement of fractional flow reserve to assess the functional severity of coronary‑ artery stenoses. N Engl J Med 1996; 334: 1703– 1708.

9. Bartunek J, Marwick TH, Rodrigues AC et al. Dobutamine‑induced wall motion abnormalities: correlations with myocardial fractional flow reserve and quantitative coronary angiography. J Am Coll Cardiol 1996; 27: 1429– 1436.

10. Pijls NH, van Schaardenburgh P, Manoharan G et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5‑year follow‑up of the DEFER Study. J Am Coll Cardiol 2007; 49: 2105– 2111.

11. Yamaguchi T, Terashima M, Akasaka T et al. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol 2008; 101: 562– 567. doi: 10.1016/ j.amjcard.2007.09.116.

12. Matsumoto D, Shite J, Shinke T et al. Neointimal coverage of sirolimus‑eluting stents at 6– month follow‑up: evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961– 967.

13. Windecker S, Kohl P, Alfonso F et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio‑ Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541– 2619. doi: 10.1093/ eurheartj/ ehu278.

14. Prati F, Di Vito L, Biondi‑ Zoccai G et al. Angiography alone vs. angiography plus optical coherence tomography to guide decision‑ making during percutaneous coronary intervention: the Centro per la Lotta contro l’Infarto‑ Optimisation of Percutaneous Coronary Intervention (CLI‑ OPCI) study. EuroIntervention 2012; 8: 823– 829.

15. Stone GW, Rizvi A, Newman et al. Everolimus‑eluting versus paclitaxel‑eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663– 1674. doi: 10.1056/ NEJMoa0910496.

16. Cypher sirolimus eluting coronary stent on Raptor over‑ the‑ wire delivery system – P020026: proval order. Rockwile, MD: Food and Drug Administration, 2003. [online] Available from: www.accessdata.fda.gov/ cdrh_docs/ pdf3/ P020026a.pdf.

17. Taxus Express2 paclitaxel‑eluting coronary stent system (monorail and over‑ thewire) P030025: proval order. Rockwile, MD: Food and Drug Administration, 2003. [online] Available from: www.fda.gov/ cdrh/ pdf3/ P030025.html.

18. Joner M, Finn AV, Farb A et al. Pathology of drug‑eluting stents in humans: delayed healing. J Am Coll Cardiol 2006; 48: 193– 202.

19. Serruys PW, Daemen J. Are drug‑eluting stents associated with a higher rate of late thrombosis than bare metal stents ? Late stent thrombosis: a nuisance in both bare metal and drug‑eluting stents. Circulation 2007; 115: 1433– 1439.

20. Serruys PW, Ormiston J, Onuma Y et al. Absorb trial first‑ in‑ man evaluation of a bioabsorbable everolimus‑eluting coronary stent system: two‑year outcomes and results from multiple imaging modalities. Lancet 2009; 373: 897– 910. doi: 10.1016/ S0140– 6736(09)60325– 1.

21. Gershlick A, Kandzari DE, Leon MB et al. Zotarolimus‑eluting stents in patients with native coronaryartery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007; 100: 45M– 55M.

22. Wenaweser P, Dörffler‑ Melly J, Imboden K et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748– 1752.